AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10680442 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 2% cream
Number of subjects: 60
Study 8693545 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563
Number of subjects: 60
Study 8693545 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 60
Study 1726411 — intervention group
Group type: COMPARATOR
Intervention: Selenium supplementation in the form of Se-salt (15 ppm anhydrous sodium selenite) for 5 years
Number of subjects: 0
Study 1726411 — intervention group
Group type: COMPARATOR
Intervention: Selenium supplementation in the form of Se-yeast (200 micrograms daily) for 4 years
Number of subjects: 0
Study 1726411 — intervention group
Group type: COMPARATOR
Intervention: Selenium supplementation in the form of Se-yeast (200 micrograms daily) for 2 years
Number of subjects: 0
Study 7254893 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific therapy
Number of subjects: 507
Study 7254893 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical operations
Number of subjects: 507
Study 7254893 — intervention group
Group type: COMPARATOR
Intervention: Randomised therapeutic trial
Number of subjects: 507
Study 30700174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum pepsinogen I (PGI) indicating atrophic gastritis
Number of subjects: 2132
Study 30700174 — intervention group
Group type: COMPARATOR
Intervention: Normal serum pepsinogen I (PGI)
Number of subjects: 2132
Study 30700174 — intervention group
Group type: EXPERIMENTAL
Intervention: History of gastric surgery due to benign cause
Number of subjects: 2132
Study 30700174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroscopy
Number of subjects: 2132
Study 27616192 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaving (group A)
Number of subjects: 129
Study 27616192 — intervention group
Group type: COMPARATOR
Intervention: Snipping (group B)
Number of subjects: 129
Study 27133551 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 207
Study 27133551 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 207
Study 24439655 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics treatment
Number of subjects: 796
Study 24439655 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 796
Study 22240593 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR (10-80 mg/day)
Number of subjects: 41
Study 22240593 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR (80 mg/day)
Number of subjects: 41
Study 22240593 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol IR (5-20 mg/day)
Number of subjects: 41
Study 22240593 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR
Number of subjects: 41
Study 22240593 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol IR
Number of subjects: 41
Study 19651939 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with a volar plate
Number of subjects: 45
Study 19651939 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and pin fixation
Number of subjects: 45
Study 17544156 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg IV dexamethasone (n=50)
Number of subjects: 100
Study 17544156 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n=50)
Number of subjects: 100
Study 11077907 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Mothers Programme (intervention)
Number of subjects: 76
Study 9411208 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle latency auditory evoked potentials (MLAEP) recordings
Number of subjects: 65
Study 9411208 — intervention group
Group type: COMPARATOR
Intervention: Brainstem auditory evoked potentials (BAEP)
Number of subjects: 65
Study 8477913 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg quinine HCl
Number of subjects: 32
Study 8477913 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg quinine HCl
Number of subjects: 32
Study 8477913 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg quinine HCl
Number of subjects: 32
Study 8477913 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 32
Study 3818024 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg)
Number of subjects: 7
Study 3818024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31047351 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow laser (577 nm)
Number of subjects: 40
Study 31047351 — intervention group
Group type: COMPARATOR
Intervention: Green laser (532 nm)
Number of subjects: 40
Study 27462023 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue staining
Number of subjects: 266
Study 27462023 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-staining)
Number of subjects: 266
Study 24633484 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade tracheotomy incision nursing pads
Number of subjects: 83
Study 24633484 — intervention group
Group type: COMPARATOR
Intervention: Traditional tracheotomy nursing pads
Number of subjects: 83
Study 23733756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 3,000 mg per day
Number of subjects: 409
Study 23733756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 19460872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study 18512996 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 0
Study 16189692 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic transobturator (TOT) SAFYRE sling
Number of subjects: 20
Study 16189692 — intervention group
Group type: COMPARATOR
Intervention: Autologous pubovaginal sling
Number of subjects: 20
Study 12828985 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05M lactic acid gel (6% w/v hydroxyethyl cellulose, pH 4.5) with fluoride for 7 days
Number of subjects: 40
Study 12828985 — intervention group
Group type: COMPARATOR
Intervention: 0.05M lactic acid gel (6% w/v hydroxyethyl cellulose, pH 4.5) without fluoride for 7 days
Number of subjects: 40
Study 10904044 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle unloading
Number of subjects: 7
Study 10904044 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle loading
Number of subjects: 7
Study 10904044 — intervention group
Group type: COMPARATOR
Intervention: Control (unchanged respiratory muscle work)
Number of subjects: 7
Study 8880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg plus 50, 100 or 200 mg of caffeine
Number of subjects: 161
Study 8880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 161
Study 8880847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 161
Study 8880847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 1719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (maximum tolerated dose up to 2 ng/kg/min, administered as a six-hourly intravenous infusion for two to four weeks)
Number of subjects: 728
Study 1719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 728
Study 1719654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study 30071046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 0
Study 30071046 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 26773515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic medium chain triglyceride diet (MCTD)
Number of subjects: 21
Study 26773515 — intervention group
Group type: COMPARATOR
Intervention: Standardized placebo diet
Number of subjects: 21
Study 23703980 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care support intervention (SCSI) utilizing a motivational interview
Number of subjects: 40
Study 23703980 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 22111944 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable force plate
Number of subjects: 40
Study 22111944 — intervention group
Group type: EXPERIMENTAL
Intervention: Belt mat
Number of subjects: 40
Study 22111944 — intervention group
Group type: COMPARATOR
Intervention: Contact mat
Number of subjects: 40
Study 22111944 — intervention group
Group type: COMPARATOR
Intervention: Vertec
Number of subjects: 40
Study 20163806 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean-speaking children (4-5 years)
Number of subjects: 2
Study 20163806 — intervention group
Group type: COMPARATOR
Intervention: Korean-speaking adults
Number of subjects: 2
Study 18167176 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.2%
Number of subjects: 52
Study 18167176 — intervention group
Group type: COMPARATOR
Intervention: Tear saline (control)
Number of subjects: 52
Study 16014139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal blood pressure (DBP)
Number of subjects: 603
Study 16014139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HTN)
Number of subjects: 603
Study 16014139 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 603
Study 16014139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal blood pressure (SBP)
Number of subjects: 603
Study 16014139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal or high DBP or SBP
Number of subjects: 603
Study 12839217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigg's technique using Aethoxysclerol
Number of subjects: 1622
Study 12839217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fegan's technique with Fibrovein
Number of subjects: 1622
Study 12839217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fegan's technique using a combination of Aethoxysclerol and Fibrovein
Number of subjects: 1622
Study 12839217 — intervention group
Group type: COMPARATOR
Intervention: Fegan's technique
Number of subjects: 1622
Study 11020756 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake group (n = 20)
Number of subjects: 40
Study 11020756 — intervention group
Group type: COMPARATOR
Intervention: Anesthetized group (n = 20)
Number of subjects: 40
Study 8669574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear, nose and throat training group (performed ten nasendoscopies on awake patients)
Number of subjects: 12
Study 8669574 — intervention group
Group type: COMPARATOR
Intervention: Traditional training group (performed ten nasendoscopies on anaesthetised oral surgery inpatients)
Number of subjects: 12
Study 1997235 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive-motion device with a mean interval of 75 hours a week and 12,000 cycles
Number of subjects: 51
Study 1997235 — intervention group
Group type: COMPARATOR
Intervention: Traditional early passive-motion protocol with a mean interval of 4 hours a week and 1,000 cycles
Number of subjects: 51
Study 6364334 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 2000 mg in a single dose
Number of subjects: 25
Study 6364334 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg three times daily for 5 days
Number of subjects: 25
Study 31854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (42% of patients)
Number of subjects: 1500
Study 31854293 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended therapy (58% of patients)
Number of subjects: 1500
Study 31854293 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 - 150 mmHg systolic blood pressure group
Number of subjects: 1500
Study 31854293 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure ranging between 120 and 130 mmHg
Number of subjects: 1500
Study 31854293 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean systolic blood pressure after blood pressure-lowering therapy
Number of subjects: 1500
Study 30420315 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) with Stride Management Assist (SMA)
Number of subjects: 41
Study 30420315 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 41
Study 30420315 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) with SMA
Number of subjects: 41
Study 29560078 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback (AVF) during chest compressions
Number of subjects: 98
Study 29560078 — intervention group
Group type: COMPARATOR
Intervention: Standard chest compressions without audiovisual feedback
Number of subjects: 98
Study 29560078 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chest compressions with audiovisual feedback
Number of subjects: 98
Study 26825083 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at Zusanli and Guanyuan
Number of subjects: 60
Study 24807329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aqueous 4% lidocaine
Number of subjects: 49
Study 24807329 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 49
Study 21988083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention (daily nurse-led, individual-based activities)
Number of subjects: 50
Study 21988083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention
Number of subjects: 50
Study 21988083 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 20329606 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingshen Granule (QSG), 1 bag thrice a day by oral intake for 1 month
Number of subjects: 60
Study 20329606 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional Western medical therapy + retention enema of Jiedu Xiezhuo No. II)
Number of subjects: 60
Study 20329606 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingshen Granule (QSG) + retention enema of Jiedu Xiezhuo No. II
Number of subjects: 60
Study 20329606 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (20 healthy persons)
Number of subjects: 60
Study 17563191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 243
Study 16275213 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy responders
Number of subjects: 79
Study 16275213 — intervention group
Group type: COMPARATOR
Intervention: OCD patients
Number of subjects: 79
Study 12095880 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 409
Study 12095880 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin cream 0.05%
Number of subjects: 409
Study 10463682 — intervention group
Group type: EXPERIMENTAL
Intervention: Thimerosal-preserved vaccine
Number of subjects: 0
Study 10463682 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclaved vaccine
Number of subjects: 0
Study 10463682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized vaccine
Number of subjects: 0
Study 10463682 — intervention group
Group type: COMPARATOR
Intervention: Control (fresh products)
Number of subjects: 0
Study 7607607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose infusion (15 min iv infusion at 0.185 mmol/kg BW/min)
Number of subjects: 7
Study 7607607 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 7
Study 1977761 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.150 mg, orally) followed by GHRH (1 micrograms/kg, iv) at 180 min
Number of subjects: 10
Study 1977761 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.150 mg, orally) at 0 min followed by GHRH at 60 min and again at 180 min
Number of subjects: 10
Study 1977761 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by GHRH at 60 min and again at 180 min
Number of subjects: 10
Study 1977761 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine at 0 min followed by 2 GHRH challenges (60 and 180 min later)
Number of subjects: 10
Study 632137 — intervention group
Group type: EXPERIMENTAL
Intervention: AGC (compression) system
Number of subjects: 34
Study 632137 — intervention group
Group type: COMPARATOR
Intervention: PC (peac‐clipping) system
Number of subjects: 34
Study 30932958 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 373
Study 30932958 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 373
Study 28923101 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving Durable Response (DR)
Number of subjects: 436
Study 25818049 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg of propranolol hydrochloride (β1 and β2 adrenergic receptor antagonist)
Number of subjects: 16
Study 25818049 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline cellulose (placebo pill)
Number of subjects: 16
Study 24314119 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga at home (n = 28)
Number of subjects: 83
Study 24314119 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga class with yoga instructor (n = 28)
Number of subjects: 83
Study 24314119 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 83
Study 21035395 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of blood flow (RBF) group with external compressive force of 50 mm Hg
Number of subjects: 11
Study 21035395 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group with no intervention
Number of subjects: 11
Study 19162406 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-specific group motivational enhancement intervention (n=161)
Number of subjects: 287
Study 19162406 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=126)
Number of subjects: 287
Study 17091358 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 160
Study 15612964 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast, 20 mg bd
Number of subjects: 30
Study 15612964 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhaler, 200 microg bd
Number of subjects: 30
Study 15612964 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline, 200 mg bd
Number of subjects: 30
Study 12572722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine cream 11% (group A)
Number of subjects: 64
Study 12572722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine solution 1% (group B)
Number of subjects: 64
Study 12572722 — intervention group
Group type: COMPARATOR
Intervention: Boric acid (group C)
Number of subjects: 64
Study 9435425 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (0.125 U/kg per week for 1 month and 0.25 U/kg per week for 5 months)
Number of subjects: 166
Study 9435425 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 166
Study 7642756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 32
Study 7642756 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 32
Study 7642756 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 32
Study 2568817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 370 (2 ml/kg body weight)
Number of subjects: 0
Study 2568817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 370 (2 ml/kg body weight)
Number of subjects: 0
Study 2568817 — intervention group
Group type: COMPARATOR
Intervention: Sodium meglumine diatrizoate 370 (2 ml/kg body weight)
Number of subjects: 0
Study 411723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (Diabenese)
Number of subjects: 0
Study 411723 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (Daonil)
Number of subjects: 0
Study 31604062 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 g (250 kcal) pistachios consumed mid‐morning
Number of subjects: 60
Study 31604062 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained current eating habits
Number of subjects: 60
Study 31634286 — intervention group
Group type: EXPERIMENTAL
Intervention: TCC early intervention (patient education, peer visits, coaching calls)
Number of subjects: 787
Study 28178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sacral lateral branch blocks
Number of subjects: 40
Study 28178092 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided sacral lateral branch blocks
Number of subjects: 40
Study 26449617 — intervention group
Group type: COMPARATOR
Intervention: AMG 403 (1, 3, 10, or 30 mg intravenously; or 10 or 30 mg subcutaneously)
Number of subjects: 66
Study 26449617 — intervention group
Group type: COMPARATOR
Intervention: AMG 403 (3, 10, or 20 mg subcutaneously once monthly for four doses)
Number of subjects: 66
Study 26449617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24106072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (optimized dose)
Number of subjects: 140
Study 22042739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner embedded in a resident team
Number of subjects: 0
Study 22042739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nurse practitioner)
Number of subjects: 0
Study 19344824 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator classification of retinal vein occlusion
Number of subjects: 682
Study 19344824 — intervention group
Group type: COMPARATOR
Intervention: Reading Center classification of retinal vein occlusion
Number of subjects: 682
Study 16784743 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine formula
Number of subjects: 0
Study 16784743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15068413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 64
Study 15068413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 64
Study 15068413 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 64
Study 11398593 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with osteoporosis and severe osteoporosis
Number of subjects: 53
Study 11398593 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy women at perimenopausal age)
Number of subjects: 53
Study 11398593 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with osteopenia
Number of subjects: 53